Roxna is a UK and European qualified patent attorney with a technical background in Microbiology and Immunology. She has in-depth knowledge and experience with viral cancer therapeutics, antibodies, microbiome, stem cells, immunotherapy, genetics and food science. Roxna has in-house patent experience working at the small biotechnology company Oncolytics Biotech Inc. and at the multinational company General Electric Healthcare and Merck Sharp & Dohme.
Roxna has experience working before the EPO, UKIPO and WIPO, including drafting and filing applications, prosecution and EPO oppositions and appeals. Roxna also has extensive experience with IP due diligence, validity opinions and FTO analysis. Having worked both in house and in private practice, Roxna is well placed to provide business focused strategic intellectual property advice to her clients.
Roxna is a named inventor on a patent for a method of purifying viruses using gel permeation chromatography. Roxna developed and ran industry-focused intellectual property courses in London UK. In particular Roxna has taught Freedom to Operate courses for the Life Sciences and Pharmaceutical Industry.
Having grown up in Canada and worked in Switzerland, Roxna is fluent in English and French.
Microbiology and Immunology
Management of Intellectual Property
November 21st 2023
A patent is a legal right that enables the patent holder to prevent others from making and using their invention in the country where the patent is granted. To many …Read article
Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …Read article
HGF is pleased to invite you to our upcoming German-language webinar in cooperation with the BVIZ on “In- and Out-licensing of Technologies” on 16th of November 2023. The webinar will …Event details
The advent of commercial launch capabilities has opened up space as a unique frontier for innovation. However, in space, any acts of patent infringement almost always go unseen. Thus, it’s …Read article
Any communications sent from the EPO on or after 1 November 2023 will no longer have the “ten day rule” applied to them. This means that communications are deemed to …Read article
HGF is pleased to invite you to our upcoming German-language seminar on “In- and Out-licensing of Technologies” in Salzburg and Dresden. The seminar will offer you the opportunity to gain …Event details
Bioforward, OBN’s ‘Roadmap for Growth’ Life Sciences event is set to take place at The King’s Centre in Oxford on Tuesday 26th September 2023. This event is designed to provide the support, skills, know-how …Event details
The integration of artificial intelligence (AI) into healthcare has ushered in a new era of personalised medicine, promising more effective and tailored treatments for patients. Traditional medical approaches often adopt …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.